License Agreements - 2022 Lilly License (Details) - License agreement with Lilly - USD ($) $ in Millions |
Jun. 30, 2026 |
Dec. 08, 2022 |
|---|---|---|
| License Agreements | ||
| Maximum amount of development and regulatory milestone payments | $ 155.0 | |
| Maximum amount of sales milestone payments | $ 440.0 | |
| Contingent payments due | $ 0.0 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Represents the maximum amount of development and regulatory milestone payments based on respective thresholds of net sales of products (developed from the licensed compound) (the "Products") in asset acquisition. No definition available.
|
| X | ||||||||||
- Definition Represents the maximum amount of sales milestone payments based on respective thresholds of net sales of products (developed from the licensed compound) (the "Products") in asset acquisition. No definition available.
|
| X | ||||||||||
- Definition The amount of contingent payments due. No definition available.
|
| X | ||||||||||
- Details
|